These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 31974807)

  • 1. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.
    Schneider SA; Alcalay RN
    J Neurol; 2020 Mar; 267(3):860-869. PubMed ID: 31974807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.
    von Linstow CU; Gan-Or Z; Brundin P
    Transl Neurodegener; 2020 Oct; 9(1):39. PubMed ID: 33066808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.
    Senkevich K; Rudakou U; Gan-Or Z
    Neuropharmacology; 2022 Jan; 202():108822. PubMed ID: 34626666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism.
    Schneider SA; Hizli B; Alcalay RN
    Neurotherapeutics; 2020 Oct; 17(4):1378-1392. PubMed ID: 32914362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
    Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
    Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Mirelman A; Thaler A
    Mov Disord; 2020 Jul; 35(7):1249-1253. PubMed ID: 32353202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
    Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
    Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
    da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
    J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
    Thaler A; Kozlovski T; Gurevich T; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A
    Mov Disord; 2018 Oct; 33(10):1656-1660. PubMed ID: 30288804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variants in PSMB9 and FGR differentially affect Parkinson's disease risk in GBA and LRRK2 mutation carriers.
    Shani S; Goldstein O; Gana-Weisz M; Bar-Shira A; Thaler A; Gurevich T; Mirelman A; Giladi N; Alcalay RN; Orr-Urtreger A
    Parkinsonism Relat Disord; 2023 Jun; 111():105398. PubMed ID: 37116292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
    Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
    Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genetic background of Parkinson's disease and novel therapeutic targets.
    Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
    Expert Opin Ther Targets; 2022 Oct; 26(10):827-836. PubMed ID: 36524726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occupational Pesticide Exposure in Parkinson's Disease Related to GBA and LRRK2 Variants.
    Brown EG; Goldman SM; Coffey CS; Siderowf A; Simuni T; Meng C; Brumm MC; Caspell-Garcia C; Marek K; Tanner CM;
    J Parkinsons Dis; 2024; 14(4):737-746. PubMed ID: 38820021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease.
    Liu SY; Zheng Z; Gu ZQ; Wang CD; Tang BS; Xu YM; Ma JH; Zhou YT; Feng T; Chen SD; Chan P;
    Parkinsonism Relat Disord; 2018 Dec; 57():72-76. PubMed ID: 30119933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left corticospinal tract could be a biomarker to identify the dual prodromal LRRK2/GBA mutated Parkinson's disease.
    Lin F; Ruan X; Zou X; Weng H; Zeng Y; Zheng J; Ye Q; Meng F; Chen X; Cai G
    CNS Neurosci Ther; 2024 Jun; 30(6):e14728. PubMed ID: 38837664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews.
    Dagan E; Schlesinger I; Kurolap A; Ayoub M; Nassar M; Peretz-Aharon J; Gershoni-Baruch R
    Dement Geriatr Cogn Disord; 2016; 42(1-2):1-6. PubMed ID: 27449028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.